Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025
Saved in:
| Published in: | MMWR Morbidity and Mortality Weekly Report |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2025
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025
- Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025
- Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025
- Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024
- Notes from the Field: Expanding Birthing Hospital Enrollment in the Vaccines for Children Program to Increase Infant Immunization Against Respiratory Syncytial Virus - United States, October 2023-March 2025
- Pediatric Respiratory Tract Infections and Circulating Influenza A Virus Subtypes
- Perioperative respiratory adverse events in children with active upper respiratory tract ...